2023-03-30 11:28:34 ET
- A phase 4 study of Takeda Pharmaceutical Co.'s ( NYSE: TAK ) Entyvio met its primary endpoint in patients with ulcerative colitis.
- Results showed that at week 14, 31% of patients on Entyvio achieved remission from chronic or recurrent pouchitis compared to 10% on placebo.
- Data also showed that at week 14, the difference in improved clinical response was 30 percentage points compared to placebo. At week 34, the difference was 22.
- Results were published in the New England Journal of Medicine .
- Read why Seeking Alpha contributor Individual Trader rates Takeda ( OTCPK:TKPHF ) a hold.
For further details see:
Takeda's Entyvio meets primary endpoint in post-market study